Leica Biosystems and Bio-Techne have launched the CE-IVD marked RNAscope In Situ Hybridization Detection Kit for automation on the BOND-III platform in Europe.

Bio-Techne’s RNAscope together with Leica’s platform will enable pathologists to access the leading applications to support their diagnostics labs.

The technology improves on traditional ISH methodologies through higher target sensitivity and specificity. It detects RNA expression patterns and localisation at the single-cell level with spatial and morphologic context.

Bio-Techne Diagnostics and Genomics Segment president Kim Kelderman said: “We are excited to expand our Leica partnership with the launch of our CE-IVD marked detection kit in Europe.

“Diagnostic labs will now have access to the fully automated RNAscope technology, providing pathologists with a powerful new tool to evaluate biomarkers involved in cancer, infection and other important human diseases.”

The RNAscope technology is said to be highly sensitive and specific due to its double Z probe design.

It provides an extremely high signal-to-noise ratio of staining in various tissue types and enables diagnostic pathologists to visualise, localise and quantify biomarker expression simultaneously.

Leica Biosystems Advanced Staining and Imaging global vice-president Colin White said: “During these difficult times and the ever-changing world due to Covid-19, we are excited about this innovative product as it delivers the benefit of improved workflow, reduced hands-on time and provides our European pathology partners an additional tool in their IVD toolbox against various diseases.”

Last month, Leica Biosystems received the US Food and Drug Administration’s (FDA) emergency use authorisation (EUA) for its Aperio ImageScope DX Viewer for remote diagnosis of Covid-19.